NDA 209445, held by Shionogi. Cefiderocol Sulfate Tosylate.
As of Nov 15, 2026, NDA 209445 (Fetroja), held by Shionogi, was first approved by FDA on Nov 14, 2019, with 4 approved supplements and 0 published complete response letters.
FETROJA is a cephalosporin antibacterial indicated in patients 18 years of age or older for the treatment of the following infections caused by susceptible Gram-negative microorganisms: Complicated Urinary Tract Infections (cUTI), including Pyelonephritis Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (HABP/VABP) To reduce the development of drug-resistant bacteria and maintain the effectiveness of FETROJA and other antibacterial drugs, FETROJA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. 1.1 Complicated Urinary Tract Infections (cUTIs), Including Pyelonephritis
| Sep 25, 2020 | Supplement 2Efficacy (new indication or use) · Priority review | Approved | |
| Nov 14, 2019 | Original applicationNew molecular entity · Priority review | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| FetrojaEQ 1GM BASE/VIAL · powder;intravenous | Cefiderocol Sulfate Tosylate | RxReference drug |
| Jul 1, 2026 | Supplement 12Labeling · Standard review | Approved | |
| Jun 6, 2025 | Supplement 9Labeling · Standard review | Approved | |
| Nov 12, 2021 | Supplement 4Labeling · Standard review | Approved | |
| Sep 25, 2020 | Supplement 2Efficacy (new indication or use) · Priority review | Approved | |
| Nov 14, 2019 | Original applicationNew molecular entity · Priority review | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters